Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Kardigan is a biopharmaceutical company developing personalized medicines for cardiovascular diseases using a proprietary R&D platform.

RhyGaze is a biotechnology company developing gene therapies for vision restoration in retinal diseases.

Tenvie Therapeutics is a biotechnology company developing small molecule therapeutics for neurological, cardiometabolic, and ophthalmic diseases.

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Rippl is a virtual dementia care company focused on providing tech-driven care solutions and expanding its network of healthcare providers for senior-focused behavioral health.

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.

eGenesis is a biotechnology company developing genetically engineered organs to address the global organ shortage, with a focus on advancing their lead product candidate for kidney transplants.

Arsenal Biosciences, Inc. is a clinical-stage company developing programmable T cell therapies for solid tumor cancers using a computationally driven approach.

Quantum Circuits develops high-fidelity quantum computers with intrinsic error detection and handling.

Gate Bioscience is a biotechnology company that has developed a scientific platform to create Molecular Gates, small molecules that target and eliminate disease-causing extracellular proteins, and has raised $60M in a Series A funding round to advance its proprietary Molecular Gate Discovery Platform.

Magnet Biomedicine is a biotechnology company that develops TrueGlues compounds to induce cooperative protein-protein interactions, aiming to optimize therapeutic impact and address undruggable proteins in areas such as cancer, cardiovascular disease, and immune disorders.

Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.